Predicine to Present Data that Highlight Comprehensive Liquid Biopsy Solutions at 2021 ASCO-GU Cancers Symposium

Data presentations to show clinical utility of Predicine’s urine- and blood-based liquid biopsy solutions for precision cancer care and clinical drug development.

Predicine announced today that new liquid biopsy data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancer Symposium, taking place from February 11-13, 2021. Among featured highlights are the urine- and blood-based liquid biopsy study in bladder cancer and prostate cancer, providing the oncology community with optimism of the urine- and blood-based approach to non-invasive diagnosis and monitoring of bladder and prostate cancers.

The first study (Poster # 491) will present the robustness and superior performance of urine-based liquid biopsy than blood in non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) setting, demonstrating the clinical utility of urine-based liquid biopsy treatment selection, disease monitoring, and early cancer detection.

The second study (Poster # 486) to be presented is a phase II clinical trial (NCT03113266) applying the blood-based PredicineATLAS assay to measure mutational landscape and blood TMB towards personalized anti-PD-1 immunotherapy (toripalimab) in metastatic urothelial carcinoma (mUC).

The third study (Poster # 159) will be presented in metastatic castration-resistant prostate cancer, demonstrating the clinical impact of blood-based detection of copy number variations (CNVs) in the PTEN-PI3K-AKT and AR pathway, especially PTEN copy number loss.

The fourth study (Poster # 99) will be presented in metastatic castration-resistant prostate cancer, where Predicine blood-based liquid biopsy assay is used for simultaneous profiling of Androgen Receptor splicing variants, hotspot mutations and amplifications at both cfDNA and cfRNA levels.

“Our priority at Predicine is to bring cutting-edge liquid biopsy solution to advance the treatment of cancer patients across the disease continuum. The focus of our blood- and urine-based liquid biopsy solution at ASCO GU 2021 is reflective of our patient-centric approach to GU cancer,” said Dr. Shidong Jia, Founder and CEO of Predicine. “We look forward to its clinical application in personalized patient care and clinical drug development”.

Notable data that will be presented at the meeting is listed below. All posters will be available for viewing on demand via the Genitourinary Cancers Symposium website from February 11 through February 13, 2021.

Abstract 491
Superior molecular pathology of urothelial bladder cancer using urinary cell-free DNA.
Click here to view poster.

Abstract 486
Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study
Click here to view poster.

Abstract 159
Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.
Click here to view poster.

Abstract 99
Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).
Click here to view poster

View official press release here.

Leave a Reply